



Improving access.
Transforming health.

December 8, 2025

The Honorable Andy Kim
520 Hart Senate Office Building
Washington, DC 20510

The Honorable Susan Collins
413 Dirksen Senate Office Building
Washington, DC 20510

Dear Senators Kim and Collins,

On behalf of the Patient Access Network (PAN) Foundation and the patients and families we assist, I write in support of the NIH Clinical Integrity Act. PAN applauds you for reintroducing this important legislation that seeks to bolster participation in NIH funded clinical trials to ensure that treatments and interventions are safe and effective for all patient populations.

As a leading charitable foundation and healthcare advocacy organization, the PAN Foundation is dedicated to accelerating access to treatment for those who need it most and empowering patients on their healthcare journeys. We provide critical financial assistance for treatment costs, advocate for policy solutions that expand access to care, and deliver education on complex topics—all driven by our belief that everyone deserves access to affordable, equitable healthcare.

Despite racial and ethnic minorities making up over 40% of the U.S. population, they remain chronically underrepresented in clinical trials. In 2021, nearly 74% of participants in FDA-approved drug trials were white, highlighting a troubling disparity given the disproportionate impact of certain diseases on minority groups. Limited diversity in clinical trials, which goes beyond racial and ethnic group representation, can result in skewed data that threatens real-world application of trial findings.

Reflecting America's diversity in clinical trial participation is important as people may experience the same disease differently. Clinical trials should include people with a variety of lived experiences and living conditions, as well as characteristics like race and ethnicity, age, sex, and sexual orientation, so that all communities can benefit from scientific advances. The NIH Clinical Integrity Act importantly seeks to increase such populations in NIH clinical trials.

The PAN Foundation appreciates your leadership in seeking solutions to increase participation in clinical trials and improve health outcomes for all Americans. We look forward to working with you to educate on the importance of passing your legislation. If you would like further information or have questions, please contact Amy Niles, Chief Mission Officer at aniles@panfoundation.org.

Sincerely,

A handwritten signature in black ink that reads 'Kevin L. Hagan'.

Kevin L. Hagan
President and Chief Executive Officer